The patent is intended to protect, inter alia, the chemical structure of the active ingredient for the treatment of glaucoma. The patent is also covering the release of the active ingredient from the Eye-D subconjunctival insert and its use in treating elevated intra-ocular pressure in patients with glaucoma and ocular hypertension. The patent and its registration will be in effect at least until April 2030.
ViSci holds an exclusive option from Novaer to a worldwide exclusive license for any use of the insert’s proprietary technology.
Use of such insert is an effective therapeutic solution to the well-known poor compliance rates with chronic eye-drop administration in ophthalmology.
Recently ViSci has successfully completed an ocular toxicology and safety study in animals and has filed an Investigational New Drug (IND) with the US Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its Eye-D Latanoprost controlled release insert for the treatment of glaucoma. The study will be conducted at up to seven investigative sites in the US.
Suzana Nahum-Zilberberg, BioLight’s chief executive officer said, "We believe that our Eye-D controlled-release insert will provide an effective solution to the well-known poor compliance with chronic eye-drop administration commonly used today as a treatment for glaucoma. This U.S. patent approval will strengthen our business, marketing and competitive advantages of our company."